WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follows the […]
Category Archives: Pr Newswire
Pr Newswire
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
24
Feb
Feb
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, […]
Pr Newswire
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
24
Feb
Feb
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on […]
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 24, 2026 /PRNewswire/ — On February 23, Illumina, Inc. (NASDAQ: ILMN) […]
COURBEVOIE, France, Feb. 24, 2026 /PRNewswire/ — IDEMIA Secure Transactions (IST), a global leader in connectivity and security solutions, is now providing Hyundai Motor Group (HMG), one of the world’s largest automakers, its advanced car connectivity management solution. Thanks to IST’s eSIM and Connectivity Manager, this collaboration marks a significant milestone in new generation connected […]
SINGAPORE, Feb. 24, 2026 /PRNewswire/ — China Yuchai International Limited (NYSE: CYD) (“China Yuchai” or the “Company”), one of the largest powertrain solution manufacturers through its main operating subsidiary in China, Guangxi Yuchai Machinery Company Limited (“Yuchai”), announces today its unaudited consolidated financial results for the 2025 second half year (“2H 2025”) and the fiscal year ended […]
TAIPEI, Feb. 24, 2026 /PRNewswire/ — As the global financial insurance landscape continues to evolve, marked by increasing information transparency and growing consumer risk awareness, professional business operations have become essential for industry practitioners worldwide to achieve sustainable development. Founded in 1998 by IMM International, the International Dragon Award (IDA) upholds the professional philosophy of “Paragon, […]
Strategic expansion into prime Sydney CBD office anchors OUE REIT’s next growth phase with enhanced portfolio quality and geographical diversity Distribution Per Unit (“DPU”)-accretive acquisition opportunity of a rare prime freehold office asset in Sydney CBD’s Core Precinct, with nearly full occupancy, long Weighted Average Lease Expiry (“WALE”) and strong Environmental, Social, and Governance (“ESG”) […]
24
Feb
Feb
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences: TD Cowen 46th Annual Health Care Conference Date:Fireside chat:Place:Webcast Link: Monday, March […]
24
Feb
Feb
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has placed a […]